Back to All Services
Our Services
Health Economics Research
At Medicys we partner with, and are preferred suppliers to, many leading health economics firms who focus on measuring and valuing the outcomes of healthcare interventions and who seek to understand how to navigate regulatory frameworks and Health Technology Assessment processes.
Specifically, our pricing and market access specialists recruit, interview and report on our network of local, regional and national payers (and ex payers) and Payer Advising Key Opinion Leaders (PA-KOLs) on topics such as:
- Economic Evaluation
- Cost of illness
- Cost comparison, effectiveness, utility and benefit
- Thresholds and opportunity costs
- Value driven healthcare systems
- Health Policy and Regulatory frameworks
- Approval and labelling
- Pricing Policy and pricing Schemes
- Reimbursement and access
- Insurance systems and national healthcare
- Public spending and national health expenditures
- Procurement systems
- Risk sharing approaches
- Health Technology Assessment
- Systems and structure
- Value framework and dossier format
- Decisions and deliberative processes
Our projects in this discipline usually take the form of Web Assisted Telephone Depth Interviews (WATDIs), online groups or advisory boards (digital or in person).
Related Work
See all Work
health economics research
+4
Pharmacy Director/Head of Pharmacy, VP/Director of Purchasing, Pharmacists/Pharmacy technicians, Directors of Nursing / Nurse Managers
To understand the decision making process for the purchase of automated dispensing cabinets
health economics research
Myelodysplastic syndrome
To assess price sensitivity of physicians in the treatment of adult patients with myelodysplastic syndrome (MDS).
health economics research
+2
Key Opinion Leaders (KOLs), respiratory physicians
Talking to key decision makers in the area of respiratory infections, specifically SARS-CoV2, respiratory pandemics and also infectious rhinitis and rhinosinusitis. Understand views on the treatment and management of respiratory infections, and the impact that a new treatment may have on this therapeutic area in the future. Discuss the potential pricing and reimbursement implications a new product may have on this therapy area
health economics research
To understand the requirements for a new PDE4 inhibitor to be reimbursed at appropriate price of new drug, assuming generic X is and is not yet launched
Request a quote
